Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Brand Name
Farxiga
Generic Name
Dapagliflozin
Active Ingredient
Dapagliflozin PropanediolCategory
Other
Variants
6
Different strengths and dosage forms
| Strength | Form | Route | NDC |
|---|---|---|---|
| 10 mg/1 | TABLET, FILM COATED | ORAL | 50090-3481 |
| 5 mg/1 | TABLET, FILM COATED | ORAL | 55154-6932 |
| 5 mg/1 | TABLET, FILM COATED | ORAL | 0310-6205 |
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Farxiga, you must consult a qualified healthcare professional.
| 5 mg/1 | TABLET, FILM COATED | ORAL | 50090-3482 |
| 10 mg/1 | TABLET, FILM COATED | ORAL | 55154-6933 |
| 10 mg/1 | TABLET, FILM COATED | ORAL | 0310-6210 |
Detailed information about Farxiga
Dapagliflozin Propanediol is a potent SGLT2 inhibitor used to manage type 2 diabetes, heart failure, and chronic kidney disease by promoting glucose excretion through the kidneys.
The dosage of Dapagliflozin Propanediol is highly standardized but must be individualized based on the patient's specific medical condition and renal (kidney) function.
As of 2024-2026 guidelines, Dapagliflozin Propanediol is primarily approved for use in adults (18 years and older). While some clinical trials have explored the use of SGLT2 inhibitors in pediatric populations with type 2 diabetes (ages 10-17), safety and efficacy have not been as extensively established as in adults. Use in children must be strictly supervised by a pediatric endocrinologist and is generally considered off-label or restricted to specific regulatory approvals in certain regions.
Renal function must be assessed via eGFR before starting Dapagliflozin Propanediol and periodically thereafter.
No specific dosage adjustment is required based on age alone. However, elderly patients (65 and older) are more likely to have decreased renal function and a higher risk of volume depletion (dehydration). Healthcare providers often monitor blood pressure and kidney labs more frequently in this population.
If you miss a dose, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and return to your regular schedule. Do not take two doses at the same time to make up for a missed one, as this increases the risk of side effects like dehydration or low blood sugar.
In the event of an overdose, contact your local poison control center or seek emergency medical attention immediately. Symptoms of a significant overdose may include severe dehydration, dizziness, rapid heartbeat, or signs of ketoacidosis (nausea, vomiting, abdominal pain). Treatment is supportive, focusing on rehydration and monitoring electrolyte levels.
> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop taking the medication without medical guidance, as this could lead to a rapid increase in blood sugar or worsening of heart failure symptoms.
Because Dapagliflozin Propanediol works by increasing glucose in the urine, it creates an environment where bacteria and fungi can thrive. The most common side effects include:
Dapagliflozin Propanediol is a potent medication that affects fluid balance and metabolic processes. It is essential for patients to remain hydrated and to monitor for signs of metabolic distress. This medication should only be used under the strict supervision of a healthcare professional who can perform regular blood and urine tests.
As of 2026, there are no FDA black box warnings for Dapagliflozin Propanediol. It has a well-established safety profile when used according to guidelines.
There are few absolute contraindications for drug combinations with Dapagliflozin Propanediol, but the following require extreme caution:
There are certain conditions where Dapagliflozin Propanediol must NEVER be used because the risks far outweigh any potential benefits:
Dapagliflozin Propanediol is not recommended during the second and third trimesters of pregnancy. Based on animal data, the drug may affect renal development and maturation in the fetus.
It is not known if Dapagliflozin Propanediol passes into human breast milk. However, because animal studies show the drug is excreted in milk and can affect the developing kidneys of the offspring, breastfeeding is generally not recommended while taking this medication. Mothers should discuss alternative treatments or formula feeding with their healthcare provider.
Dapagliflozin Propanediol is a potent and competitive inhibitor of the Sodium-Glucose Cotransporter 2 (SGLT2). SGLT2 is expressed almost exclusively in the S1 segment of the proximal convoluted tubule in the kidney. By binding to this transporter, Dapagliflozin prevents the reabsorption of filtered glucose back into the tubular capillaries. This leads to the excretion of approximately 70 grams of glucose per day in the urine. Additionally, because sodium reabsorption is coupled with glucose reabsorption in this transporter, the drug also causes natriuresis (sodium loss). This reduction in sodium reabsorption helps restore the tubuloglomerular feedback mechanism, leading to afferent arteriolar vasoconstriction and a reduction in high pressure within the kidney (hyperfiltration), which is the primary mechanism for its kidney-protective effects.
Common questions about Farxiga
Dapagliflozin Propanediol is primarily used to manage three major chronic conditions: type 2 diabetes, heart failure, and chronic kidney disease. In type 2 diabetes, it helps lower blood sugar levels by allowing excess glucose to be removed through the urine. For heart failure patients, it reduces the risk of hospitalization and cardiovascular death by easing the workload on the heart. In patients with chronic kidney disease, it is used to slow the progression of the disease and prevent the need for dialysis. It is often prescribed alongside other medications like metformin or ACE inhibitors. Your healthcare provider will determine which of these indications applies to your specific health profile.
The most common side effects are related to the increased glucose in the urinary tract, which can lead to genital yeast infections and urinary tract infections (UTIs). Many patients also experience an increase in the frequency and volume of urination, which is how the drug removes sugar from the body. Some people may feel slightly dizzy or lightheaded, especially when first starting the medication, due to a mild drop in blood pressure. Thirst and back pain are also frequently reported in clinical studies. Most of these side effects are manageable, but you should report any persistent discomfort to your doctor. Proper hygiene and staying hydrated can help reduce the risk of some of these issues.
You should exercise extreme caution when drinking alcohol while taking Dapagliflozin Propanediol. Alcohol can significantly increase your risk of developing diabetic ketoacidosis (DKA), a life-threatening condition where the blood becomes too acidic. It also contributes to dehydration, which can worsen the side effects of the medication on your kidneys. Furthermore, alcohol can interfere with your blood sugar levels, making it harder to manage your diabetes effectively. If you choose to drink, it should be in moderation and always accompanied by food. Always discuss your alcohol consumption habits with your healthcare provider to ensure your safety.
Dapagliflozin Propanediol is generally not recommended during pregnancy, particularly in the second and third trimesters. Research suggests that the drug may interfere with the normal development of the baby's kidneys during these stages. If you are planning to become pregnant or find out you are pregnant while taking this medication, you should contact your doctor immediately. Most healthcare providers will recommend switching to insulin, which is considered safer for managing blood sugar during pregnancy. There is also limited information on whether the drug passes into breast milk, so breastfeeding is typically discouraged while on this therapy. Your doctor will help you weigh the risks and benefits for your specific situation.
The blood-sugar-lowering effects of Dapagliflozin Propanediol begin relatively quickly, often within the first 24 hours of the first dose, as the kidneys start excreting glucose. However, it may take one to two weeks of consistent use to see a significant and stable drop in your overall blood glucose levels. For conditions like heart failure and chronic kidney disease, the benefits are more long-term and may not be 'felt' immediately by the patient. In these cases, the drug works over months and years to protect your organs from further damage. It is important to continue taking the medication exactly as prescribed, even if you do not notice an immediate change in how you feel.
You should never stop taking Dapagliflozin Propanediol suddenly without first consulting your healthcare provider. Abruptly discontinuing the medication can cause your blood sugar levels to spike rapidly, which can lead to symptoms of high blood sugar like extreme thirst and blurred vision. For those taking it for heart failure or kidney disease, stopping the drug could lead to a sudden worsening of your condition or fluid buildup. If you need to stop the medication for a medical procedure or due to a side effect, your doctor will provide a specific plan to do so safely. Always keep a steady supply of your medication to avoid missing doses.
If you miss a dose of Dapagliflozin Propanediol, take it as soon as you remember that same day. However, if it is nearly time for your next scheduled dose, you should skip the missed dose entirely and simply take your next dose at the regular time. Do not take two tablets at once to 'catch up,' as this can increase your risk of dehydration or low blood sugar. Setting a daily alarm or using a pill organizer can help you remember to take your medication at the same time each day, which is usually in the morning. If you frequently miss doses, talk to your pharmacist about strategies to help you stay on track with your treatment.
No, Dapagliflozin Propanediol is actually associated with modest weight loss rather than weight gain. Because the medication causes the body to excrete glucose (which contains calories) through the urine, most patients lose an average of 4 to 7 pounds over the first few months of treatment. This is often seen as a beneficial side effect, especially for patients with type 2 diabetes who are also managing their weight. The weight loss is usually a combination of both calorie loss and a small amount of fluid loss due to the drug's mild diuretic effect. However, it should not be used as a primary weight-loss medication. If you experience sudden or extreme weight loss, you should contact your healthcare provider.
Dapagliflozin Propanediol is frequently taken with other medications, but some combinations require careful monitoring. It is commonly used alongside metformin, DPP-4 inhibitors, or insulin for diabetes. However, taking it with insulin or sulfonylureas increases the risk of low blood sugar, requiring dose adjustments. It also interacts with 'water pills' (diuretics), which can lead to excessive dehydration. There is a specific interaction with lithium where the drug may lower lithium levels in the blood, making it less effective. Always provide your doctor with a complete list of all prescriptions, over-the-counter drugs, and herbal supplements you are taking to prevent dangerous interactions.
Generic versions of Dapagliflozin have been approved by the FDA and are becoming increasingly available in various markets. The availability of a generic version often depends on the patent status in your specific country. Generic medications contain the same active ingredient and meet the same rigorous safety and quality standards as the brand-name version (Farxiga). Choosing a generic can often reduce your out-of-pocket costs significantly. You should check with your pharmacist or insurance provider to see if a generic version is covered under your plan. Regardless of whether you take the brand-name or generic version, the clinical effects and safety profile remain the same.
Other drugs with the same active ingredient (Dapagliflozin Propanediol)
While rare, some side effects are life-threatening and require emergency care.
> Warning: Stop taking Dapagliflozin Propanediol and call your doctor immediately if you experience any of these:
No FDA black box warnings currently exist for Dapagliflozin Propanediol. Unlike some other drugs in the SGLT2 class (like Canagliflozin), Dapagliflozin does not carry a black box warning for lower limb amputation, though healthcare providers still advise routine foot care for all diabetic patients.
Report any unusual symptoms to your healthcare provider. Early detection of side effects like yeast infections or dehydration can prevent them from becoming serious medical issues.
Your healthcare provider will likely require the following tests:
Dapagliflozin Propanediol generally does not affect the ability to drive. However, if you experience dizziness due to low blood pressure or shakiness from low blood sugar (if used with insulin), do not operate heavy machinery until you feel stable.
Alcohol should be consumed with extreme caution. Alcohol can increase the risk of ketoacidosis and dehydration. It can also mask the symptoms of low blood sugar. It is generally advised to limit alcohol intake to moderate levels and always consume it with food.
Do not stop taking Dapagliflozin Propanediol suddenly unless instructed by your doctor (e.g., in the case of a serious side effect). Stopping the drug may cause a rapid rise in blood glucose levels or a sudden worsening of heart failure symptoms. There is no 'withdrawal syndrome' per se, but the underlying conditions (diabetes/HF) may rebound quickly.
> Important: Discuss all your medical conditions, including any history of pancreas problems, alcohol abuse, or frequent urinary tract infections, with your healthcare provider before starting Dapagliflozin Propanediol.
For each major interaction, the mechanism usually involves either a pharmacodynamic synergy (two drugs doing the same thing, like lowering blood pressure) or a change in renal clearance. The management strategy typically involves more frequent monitoring of lab values or adjusting the dose of the other medication.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter pain relievers and vitamins.
These are conditions where the drug may be used, but only with extreme caution and careful risk-benefit analysis by a specialist:
Patients who have had an allergic reaction to other SGLT2 inhibitors, such as Canagliflozin (Invokana) or Empagliflozin (Jardiance), may experience a cross-reaction with Dapagliflozin Propanediol. Always inform your doctor if you have had a reaction to any 'gliflozin' medication.
> Important: Your healthcare provider will evaluate your complete medical history, including your kidney function and any history of cancer or severe infections, before prescribing Dapagliflozin Propanediol.
Dapagliflozin Propanediol is not established as safe or effective in children under the age of 18 for most indications. While some regions have approved it for T2DM in children over 10, it is not used for heart failure or CKD in pediatric populations. Growth and development are not known to be affected, but the risk of ketoacidosis may be higher in younger patients.
Patients aged 65 and older are at a higher risk of:
Despite these risks, the cardiovascular and renal benefits in the elderly are significant, and the drug is frequently used with close monitoring.
No adjustment is needed for mild to moderate liver disease. In severe liver disease, the exposure to the drug increases, and a 5 mg dose is preferred as a starting point.
> Important: Special populations require individualized medical assessment. Always inform your doctor if you are planning to become pregnant or are over the age of 75.
| Parameter | Value |
|---|---|
| Bioavailability | 78% |
| Protein Binding | ~91% |
| Half-life | 12.9 hours |
| Tmax | 1-2 hours (fasted) |
| Metabolism | Primarily UGT1A9 |
| Excretion | Renal 75%, Fecal 21% |
Dapagliflozin belongs to the SGLT2 inhibitor class. Related medications include Empagliflozin (Jardiance), Canagliflozin (Invokana), and Ertugliflozin (Steglatro). It is considered a 'non-insulin-dependent' antihyperglycemic agent.